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Several pathophysiologic mechanisms have been
proposed to explain slow-healing leg ulcers, but little
is known about the growth behavior of cells in these
wounds. Platelet-derived growth factor-BB applied
topically to chronic wounds has shown beneficial
effects, although the effects have been less pronounced
than would have been expected based on studies on
acute wounds. The objective of this study was to
compare fibroblasts in culture obtained from chronic
wounds (non-healing chronic venous leg ulcers), acute
wounds and normal dermis regarding growth, mito-
genic response to platelet-derived growth factor-BB
and levels of platelet-derived growth factor a-receptor
and b-receptor. Fibroblasts were obtained by an
explant technique and expanded in vitro using fibroblast
growth medium supplemented with 10% fetal bovine
serum and used for the assays at their third passage.
Growth of chronic wound fibroblasts (n J 8) was
significantly (p < 0.05) decreased compared with those
from acute wounds (n J 10) and normal dermis
(n J 5). Fibroblasts from ulcers older than 3 y grew
Several pathophysiologic mechanisms have been proposedto explain slow/non-healing leg ulcers. Overproductionof reactive oxygen species, hypoxia, imbalances in levelsof cytokines and proteolytic enzymes, excessive fibrindeposition, and failure of keratinocyte migration on the
chronic wound bed have been presented as possible explanations
for the defective healing of leg ulcers (Coleridge Smith, 1994;
Falanga et al, 1994). Little is known, however, about growth and
other biologic activities of cells in these wounds.
Fibroblasts are one of the key cells in wound repair. Apart from
producing the major extracellular components of collagen, elastin,
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significantly (p < 0.01) slower than those from ulcers
that had been present for less than 3 y. Morphology
and size of fibroblasts from the oldest chronic wounds
deviated substantially from those of acute wounds and
normal dermis, and resembled in vitro aged or senescent
fibroblasts. Mitogenic response of chronic wound
fibroblasts to human recombinant platelet-derived
growth factor-BB was also reduced with ulcer age. No
significant differences were found in the amount of
either platelet-derived growth factor a-receptor or
b-receptor among the three groups. The features
decreased growth related to ulcer age, altered morpho-
logy, and reduced response to platelet-derived growth
factor, indicating that fibroblasts in some chronic
wounds have approached or even reached the end of
their lifespan (phase III). This might provide one
explanation for the non-healing state and therapy
resistance to topical platelet-derived growth factor-BB
of some venous leg ulcers. Key words: ageing/growth
factors/senescence/wound healing. J Invest Dermatol
112:463–469, 1999
and proteoglycans, fibroblasts also make mitogens for keratinocytes,
fibroblasts, and endothelial cells (Werner et al, 1994). Fibroblasts
probably migrate from neighboring tissues, although a bloodborne
origin has also been proposed (Bouissou et al, 1988; Bucala et al,
1994). At the wound site, fibroblasts change into a less proliferative
but a more contractile and collagen synthetic phenotype (Regan
et al, 1991; Germain et al, 1994; Ågren et al, 1996). These functional
alterations can be mimicked in vitro by adding wound fluid to
cultured normal skin fibroblasts (Regan et al, 1991). This finding
indicates the control provided by factor(s) present in the wound
environment.
The main regulators of the cellular activities in wound repair
are polypeptide growth factors (Steenfos, 1994). Platelet-derived
growth factor (PDGF) is mitogenic and chemotactic for connective
tissue cells such as fibroblasts, and appears to be an important
autocrine and paracrine factor during wound repair (Grotendorst
et al, 1985; Ågren et al, 1996). Controlled clinical trials with one
of the three isoforms of PDGF, PDGF-BB homodimer have not
produced the same beneficial effects, however, when applied
topically to chronic wounds as when applied to acute, experimental
wounds (Robson et al, 1992; Pierce et al, 1994; Robson, 1997).
PDGF activates cells via specific cell surface receptors: α-receptor
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and β-receptor. The presence of PDGF receptors appears to be
upregulated during human wound healing compared with normal
skin, as demonstrated by in situ hybridization and immunohisto-
chemistry (Reuterdahl et al, 1993; Peus et al, 1995). Immunostaining
for both types of receptors is predominantly localized to fibroblast-
like cells in granulation tissue from both acute and chronic wounds,
whereas endothelial cells stain exclusively for the β-receptor. Pierce
et al (1994) observed that the number of fibroblasts increased in
healing chronic wounds but not in non-healing chronic wounds
treated with PDGF-BB, whereas in placebo-treated chronic wounds
no difference in fibroblast number was seen between healing and
non-healing wounds. This observation indicates that there are
fibroblasts in some chronic wounds that do not respond to PDGF-
BB, possibly due to deficient numbers of PDGF receptors or
dysfunctional intracellular signal transduction.
In order to test this hypothesis, we have compared fibroblasts
cultured from chronic as well as from acute wounds, and also from
normal skin with respect to their growth and mitogenic response
to growth factors, especially to PDGF-BB. Furthermore, the levels
of PDGF α-receptor and β-receptor on the different fibroblast
strains were estimated.
MATERIALS AND METHODS
Patients, wounds, and normal skin Fibroblasts from wounds were
obtained from eight patients [aged 68 6 5 y (mean 6 SEM), four females]
with chronic wounds (venous leg ulcers) and 10 patients (59 6 5 y, six
females) with acute wounds (traumatic), as well as from normal whole skin
of the medial upper arm of five healthy volunteers (45 6 4 y, three
females). The chronic wounds had been present for more than 6 mo
(6 mo, 1, 1.5, 3, 6, 10, 10, and 20 y), were larger than 50 cm2 in size,
and were excised for subsequent autologous skin transplantation due to
the non-healing state of the ulcers. Punch biopsy specimens (4 mm) were
also taken from adjacent, clinically diagnosed lipodermatosclerotic skin and
normal skin in five of the eight patients (aged 64 6 6 y) with chronic
wounds (1, 1.5, 6, 10, and 20 y old ulcers). The 10 acute wounds
comprised seven with 14–45 d old exuberant granulation tissue, two
expanded polytetrafluoroethylene tubes with 10 d old subcutaneous granula-
tion tissue (Jorgensen et al, 1996), and one 4 d old 6 mm punch biopsy
wound. No sites showed any clinical signs of infection. Furthermore, none
of the patients had diabetes mellitus or were given systemic antibiotics,
glucocorticoids, or chemotherapeutic agents. Informed consent was
obtained from all patients participating in the study, which was approved
by the local ethical committee.
Cell cultures Granulation tissue was obtained from central non-
epithelialized parts of the open wounds or from the expanded poly-
tetrafluoroethylene tubes and used as explants. From the normal skin 6 mm
whole dermis punch biopsies were used as explants after excision of the
epidermis. The tissue specimens were immersed in ice-cold phosphate-
buffered saline (PBS), kept at 5°C and washed three times in 50 ml ice-
cold PBS before explanting, which occurred within 4 h after harvesting.
Tissues were minced (1 mm3), explanted on 60 mm Petri dishes (Greiner,
Frickenhausen, Germany) and fibroblast outgrowth supported with
fibroblast growth medium (FGM, Clonetics, Walkersville, MD) supple-
mented with 10% heat-inactivated mycoplasma-screened fetal bovine serum
(FBS, Gibco BRL, Grand Island, NY). FGM is composed of fibroblast
basal medium (FBM) supplemented with basic fibroblast growth factor
(bFGF, 1 ng per ml, final concentration), insulin (5 µg per ml), gentamicin
(50 µg per ml), and amphotericin-B (10 ng per ml). The same batch of
serum was used throughout the study. The explant procedure was compared
with enzymatic digestion of granulation tissue obtained from the two
polytetrafluoroethylene tubes. Fibroblasts were cultured either from
explanted minced tissue as described above or from minced tissue that had
been digested with 200 U bacterial collagenase type IA (Sigma, St Louis,
MO) per ml FBM for 18 h at 37°C in a humidified atmosphere of 5%
CO2/air essentially as described by Regan et al (1991). Cell growth was
similar for the two procedures with a mean saturation density on post-
plating day 10 (see Growth kinetics below) of 6.9 3 104 for the fibroblasts
grown from explants compared with 7.3 3 104 for collagenase-treated
tissue. Initial experiments also showed that the growth of human dermal
fibroblasts, obtained from explanted skin from the posterior lower leg of
a healthy 30 y old male, increased significantly when using FGM supple-
mented with 10% FBS compared with using Dulbecco’s modified Eagle’s
medium (DMEM) with Glutamax, 4.5 g glucose per liter and supplemented
with 10% FBS. The saturation density, achieved with DMEM with 10%
FBS, was 2.1 6 0.1 3 104 compared with 1.2 6 0.1 3 105 for fibroblasts
cultured in FGM supplemented with 10% FBS. Furthermore, FGM with
10% FBS supported outgrowth of fibroblasts from chronic wound tissue.
Cultures were maintained at 37°C in a humidified atmosphere of 5%
CO2/air. Culture medium was changed twice weekly. Subcultivation was
performed using mycoplasma-tested trypsin/ethylenediaminetetraacetic acid
(EDTA) (0.05%/0.02% in PBS pH 7.4; Biological Industries, Kibbutz Beit
Haemek, Israel) and cells were split at a ratio of 3:1 at confluence (Hayflick
and Moorhead, 1961). Cells of the third passage were used for the
assays. Phase-contrast microphotography was performed using an inverted
microscope (Nikon TMS, 10 3 objective) on all fibroblast strains. Selective
cell strains were checked immunocytochemically for vimentin (Boehringer
Mannheim, Germany), cytokeratins 5, 6, 8, and 17 (M 821; DAKO,
Glostrup, Denmark), and von Willebrand factor (A 082; DAKO). All
fibroblast strains examined were found positive for vimentin, and negative
for cytokeratins and von Willebrand factor. The cell strains checked for
mycoplasma by polymerase chain reaction were found negative.
Growth kinetics Day 0, 3.5 3 103 cells per cm2 were seeded in 24
well plates (Nunc, Roskilde, Denmark) in 1 ml complete medium per
well, and enumerated 3, 4, 5, 6, 7, 8, 9, and 10 d post-plating in triplicates
using a Bu¨rker hemocytometer. Cells were re-fed with new medium days
4 and 7 during the 10 d growth period. Growth curves were generated
for each individual fibroblast strain, and the population doubling time for
the individual fibroblast strains was determined graphically during their
logarithmic growth and the fibroblast density determined at saturation
(Freshney, 1991). All wells were inspected using inverted phase-contrast
microscopy for aberrant cell behavior and for detached cells throughout
the 10 d growth period.
The effect of conditioned medium from the three groups of fibroblast
strains on cell proliferation was studied in a complementary experiment.
Fifteen milliliters of conditioned complete medium (FGM with 10% FBS)
was obtained from confluent fibroblasts, in 75 cm2 plastic flasks grown for
72 h, from chronic and acute wounds, and dermis, respectively, from the
same patients. The target cells (dermal fibroblasts) were seeded into 96
well plates (Nunc) at 3.5 3 103 cells per cm2 and 3.5 3 104 cells per cm2
and grown for 24 h, and then exposed to the conditioned media for 24 h.
Fibroblasts were also treated with unconditioned complete media. All
media were sterile-filtered (0.22 µm) before being added to the cells. Cell
proliferation was measured as incorporation of the thymidine analogue,
5-bromo-29-deoxyuridine (BrdU, 10 µM, final concentration) into the
dermal fibroblasts during the last hour of incubation. The incorporation
of BrdU was determined using an ELISA kit (Boehringer Mannheim) and
∆OD (OD370 nm – OD492 nm) read by an ELISA reader (Labsystems,
Helsinki, Finland).
In situ incorporation of BrdU To study further the proliferative ability,
one representative fibroblast strain from each group was pulse-labelled with
BrdU. Cells were seeded to about 50% confluence (104 cells per cm2) on
Chamber Glass Slides (Lab-Tek, Nunc) in complete culture medium and
incubated for 24 h. BrdU (10 µM, final concentration) was added during
the last hour of incubation. Cells were then washed three times with PBS,
fixed with glycine buffer (50 mM glycine in 70% ethanol, pH 2.0). Cells
synthesizing DNA were detected immunocytochemically using a kit from
Boehringer Mannheim.
Mitogenic response Cells were seeded into 96 well plates (Nunc) at
1 3 104 cells per well in complete medium and incubated for 72 h. The
medium was then replaced with 100 µl FBM containing 2.5% FBS per
well and the cells were incubated for another 24 h. Growth factors in
25 µl FBM containing 1% (wt/vol) bovine serum albumin (BSA, Sigma)
were added to a final volume of 125 µl and 25 µl FBM containing 1%
BSA alone to the six control wells. Human recombinant PDGF-BB,
PDGF-AA, and transforming growth factor (TGF)-β1 were obtained from
Gibco BRL. Human recombinant bFGF and epidermal growth factor
(EGF) were purchased from Sigma. Two-fold dilutions of each growth
factor were used at six final concentrations in duplicate (PDGF, 0.6–20 ng
per ml; bFGF, 0.15–5 ng per ml; EGF, 1.5–50 ng per ml; TGF-β1,
0.3–10 ng per ml). The cells were then incubated with or without growth
factors for 18 h. BrdU in FBM medium (10 µl per well) was added to all
wells to a final concentration of 10 µM except for the background control
(unspecific binding of the anti-BrdU conjugate to the cells in the absence
of BrdU), which received 10 µl of FBM medium alone. The cells were
incubated for an additional 2 h and then washed three times with PBS.
The effect of the growth factors on fibroblast proliferation was expressed
as the percentage of BrdU incorporated, measured with the ELISA described
above under Growth kinetics, into control-treated cells after subtraction of
blank values for respective growth factor.
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Figure 1. Different morphology and growth kinetics for fibroblasts
cultured from chronic wounds, acute wounds, and normal dermis.
Representative phase-contrast microphotographs of fibroblasts from chronic
wounds (a), acute wounds (b), and dermis (c) 10 d post-plating. Note the
irregular shape, large size, and sparsely growth of the chronic wound
fibroblasts (a) compared with spindle-shaped and tightly grown acute
wound (b) and normal dermal fibroblasts (c). Scale bar: 200 µm. Each
growth curve depicted on a logarithmic y-axis in (d) represents the mean
of eight different fibroblast strains from chronic wounds (s), 10 different
fibroblast strains from acute wounds (d), and five different fibroblast strains
from normal dermis (u). Error bars: SEM.
PDGF a-receptor and b-receptor quantification The number of
α-receptors and β-receptors were quantified in detergent-solubilized cell
membranes using a membrane solid phase immunoassay (slot-blot tech-
nique) with monoclonal antibodies. The immunoreactions in the slot-blots
were then quantified with densitometry, which is an established quantitative
method (Towbin and Gordon, 1984). To improve the precision of the
assay, cell membrane proteins at three 2-fold dilutions (each dilution assayed
in duplicate) from the three groups were included in the same blot. Probing
with the same concentration of the two primary antibodies against the
α-receptors and β-receptors and color development were carried out
simultaneously to decrease variability between the immunoreactions of
α-receptor and β-receptor.
Membrane extract was obtained after lysing confluent cells grown in
FGM with 10% FBS with 1% (vol/vol) Triton X-100 with 3 mM
phenylmethylsulfonyl fluoride for 30 min at 4°C (Ågren et al, 1996).
Extracts were diluted to lie within the linear range of the assay in
Tris(hydroxymethyl)-aminomethane (Tris)–HCl-buffered-saline (pH 7.4),
added to a 48 well slot-blot apparatus (Bio-Rad, Hercules, CA) and filtered
through nitrocellulose membrane (Trans-Blot, 0.45 µm, Bio-Rad). Bound
PDGF receptors were immunoreacted for 18 h at ambient temperature
with mouse monoclonal antibodies (10 ng per ml, Genzyme, Cambridge,
MA) against the human PDGF α-receptor and the human PDGF β-
receptor (10 ng per ml, Genzyme) (Hart et al, 1987). The primary antibodies
were immunoreacted for 90 min with biotinylated swine anti-mouse IgG
diluted 1:2500 (E 0453; DAKO) followed by treatment for 30 min with
streptavidin complexed with biotinylated alkaline phosphatase (K 0391;
DAKO) according to the manufacturer’s instructions. Nitro blue
tetrazolium/ 5-bromo-4-chloro-3-indolyl phosphate was applied to visual-
ize the receptor-bound complexes. The blots were scanned (Hewlett
Packard ScanJet 4). The intensities of the bands were quantified using a
software from Jandel (SigmaGel), normalized to the protein content (DC
Protein Assay Kit with bovine serum albumin as standard, Bio-Rad) of
the cell extracts and expressed as arbitrary units per µg cell protein.
Statistics Kruskal–Wallis one-way analysis of variance was applied to the
population doubling time, cell density, and PDGF-receptor data. Wilcoxon
matched-pairs signed-ranks test was applied when comparing levels of
α- and β-receptor within the three fibroblast groups. In case of statistical
significance (p , 0.05), Bonferroni’s correction for multiple hypotheses
was used to ensure that type I errors were not multiplied. The effect of
ulcer age on fibroblast growth was tested using the Student’s t-test for
unpaired observations. Numerical data are given as mean 6 SEM.
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Table I. Population doubling time was increased and saturation density decreased for chronic wound fibroblasts
Chronic wounds p Acute wounds p Normal dermis
Number of strains 8 10 5
Population doubling time (h) 118.7 6 39.7a ,0.05 32.6 6 5.5 NSb 27.9 6 3.3
Saturation density (cells per cm2 3 10–4) 2.0 6 0.7 ,0.05 8.8 6 1.7 ,0.05 15.5 6 1.9
aMean 6 SEM.
bA statistically non-significant (p . 0.05) difference.
RESULTS
Morphology and growth of the fibroblasts Fibroblasts from
acute wounds did not show any morphologic difference at a light
microscopic level compared with those from normal dermis. They
all displayed the characteristic spindle-shaped appearance and swirl
growth pattern. Chronic wound fibroblasts commonly exhibited
an altered morphology with irregular cell shape, multinucleation,
larger and more variable cell size, and accumulation of debris
(Fig 1a–c).
Although plating efficiency was not determined per se, a negligible
number of detached fibroblasts was observed in any well prior to
enumeration on the third post-plating day. Overall, chronic wound
fibroblasts grew at a slower rate than those obtained from acute
wounds and normal dermis (Fig 1d). The mean population doubling
time, as determined from the slope of the individual growth curves,
was almost four times longer for chronic wound fibroblasts than
for acute wound and dermal fibroblasts (Table I). Chronic wound
fibroblasts reached a density 10 d post-plating of about a fourth of
the cell density of fibroblasts from acute wounds and dermis
(Table I). Five of the eight chronic wound fibroblast strains
approached or reached a replicative senescent growth behavior.
Those fibroblast strains were derived from venous leg ulcers that
had been present for more than 3 y. Statistical analyses revealed
that those fibroblasts (n 5 5) grew to a statistically significantly
(p , 0.01) lower saturation cell density (6.6 6 2.0 3 103 cells per
cm2) than those from leg ulcers younger (n 5 3) than 3 y
(4.3 6 0.4 3 104 cells per cm2). The mean population doubling
time was also extended by the fibroblasts from the old ulcers
(166.8 6 53.5 h) compared with fibroblasts from ulcers younger
than 3 y (38.6 6 6.6 h), although this difference did not reach
statistical significance (p 5 0.074). Acute wound fibroblasts reached
a significantly (p , 0.05) lower saturation cell density than dermal
fibroblasts 10 d post-plating (Table I).
In five of the chronic wounds, fibroblasts of peri-wound skin
were also expanded in vitro to see if they differed from those in the
chronic wounds in terms of growth. The growth of fibroblasts
from the chronic venous leg ulcers was severely diminished
compared with those from adjacent uninjured tissues. One biopsy
from adjacent normal skin in one patient and one biopsy from
adjacent lipodermatosclerotic skin in another patient were excluded
due to interfering epithelial outgrowth from the biopsies. In the
remaining three patients, the growth of fibroblasts from peri-ulcer
lipodermatosclerotic skin appeared to be similar to fibroblasts from
normal skin of the same lower limb, which again was lower in the
chronic wounds (Table II). Thus, it appears that the fibroblasts in
the chronic wounds are different regarding cellular growth from
those of adjacent tissue.
The possibility of the chronic wound fibroblasts producing
growth inhibitory molecules that might decrease cell growth was
investigated. BrdU incorporation, expressed as ∆OD, into dermal
fibroblasts from normal skin (3.5 3 103 cells per cm2) exposed to
conditioned media for 24 h from fibroblasts derived from one
chronic wound and from adjacent normal skin was 0.449 6 0.020
(n 5 3) and 0.406 6 0.020 (n 5 2), respectively. The corresponding
results for the acute wound and adjacent skin were 0.413 6 0.026
(n 5 5) and 0.492 6 0.031 (n 5 3), respectively. Unconditioned
complete media resulted in a ∆OD of 0.780 6 0.032 (n 5 6).
Similar results were obtained when the target fibroblasts were
Table II. Population doubling time was increased and
saturation density decreased for chronic wound fibroblasts
compared with adjacent lipodermatosclerotic and normal
skin in three patients
Chronic Lipodermatosclerotic Normal
wounds dermis dermis
Population doubling 111.0 6 67.7a 45.9 6 6.7 40.4 6 4.9
time (h)
Saturation density 2.7 6 1.2 9.1 6 1.9 9.6 6 0.4
(cells per cm2 3 10–4)
aMean 6 SEM.
seeded at an initial higher density (3.5 3 104 cells per cm2). These
results thus indicate that the observed decreased growth of chronic
wound fibroblasts was not due to an autocrine suppressive
mechanism.
Further proof of a diminished proliferation of chronic wound
fibroblasts was an abolished or decreased DNA synthesis as evid-
enced by no or reduced incorporation of the thymidine analog
BrdU (Fig 2).
Mitogenic response to growth factors including PDGF-
BB and levels PDGF a-receptor and b-receptor Human
recombinant mitogens added to growth-arrested cells elicited DNA
synthesis, indicating the presence of functional receptors on the
various cell strains. BrdU-incorporation in the fibroblast strains,
however, from the four chronic wounds of the longest duration
(6, 10, 10, and 20 y) was below the limit of detection. PDGF-BB
was the most mitogenic growth factor inducing about a 15-fold
stimulation of DNA synthesis in skin fibroblasts compared with a
5–10-fold stimulation with bFGF, EGF, and PDGF-AA. TGF-β1
stimulated DNA synthesis only slightly (about 50% above control)
(Fig 3a and Table III). The maximal response to PDGF-BB
occurred at concentrations between 10 and 20 ng per ml and no
further stimulation was found at concentrations above 20 ng per
ml (data not shown). The maximal mitogenic response to PDGF-
BB and also to bFGF and EGF, however, was diminished for the
chronic wound fibroblasts compared with the acute wound and
the skin fibroblast strains (Fig 3b and Table III).
Because PDGF activates cells via specific surface receptors (types
α and β) one possible reason for the reduced response to PDGF-
BB could be a lower number of PDGF α-receptors and β-receptors
in the chronic wound fibroblasts. No statistically significant differ-
ence, however, was found among the three groups (Fig 4).
Interestingly, the amount of α-receptors was about 30% lower
(p , 0.05) than the amount of β-receptors on dermal fibroblasts,
whereas there was no significant difference between α-receptors
and β-receptors on either chronic or acute wound fibroblasts.
DISCUSSION
The pathogenesis of chronic venous leg ulcers is multifactorial
(Coleridge Smith, 1994; Falanga et al, 1994). There are only a few
studies examining cells isolated from such wounds (Roberts and
Harding, 1994; Herrick et al, 1996; Hasan et al, 1997; Stanley et al,
1997). Our results indicate that fibroblasts, crucial cells in wound
repair, isolated from chronic wounds grown under optimal in vitro
conditions have a diminished capacity to replicate. Furthermore,
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Figure 2. In situ incorporation of BrdU was severely diminished in
chronic wound fibroblasts compared with fibroblasts from acute
wounds, and normal dermis. No BrdU-positive fibroblast was found
in the chronic wound fibroblasts (a) whereas several BrdU-positive cells
(one of them arrowed in micrographs b and c) were observed amongst the
fibroblasts obtained from acute wounds (b) and normal dermis (c),
respectively. Scale bar: 100 µm.
the ability to replicate appeared to decline with the duration of the
ulcers from which the fibroblasts were isolated. Because decreased
fibroblast proliferation appears to correlate to a correspondingly
slower wound healing, at least experimentally in hamsters (Bruce
and Deamond, 1991), this is a possible explanation for the reduced
healing ability of chronic venous leg ulcers.
Stanley et al (1997) recently reported decreased growth of
fibroblasts cultured from venous leg ulcers compared with fibroblasts
cultured from the normal thigh skin of the same six patients. We
also found a severely decreased growth of fibroblasts from the
venous ulcers compared with those from adjacent peri-ulcer skin
in the same patients. Because fibroblasts in wounds exhibit a
different phenotype, e.g., decreased proliferative ability, compared
Figure 3. Dose–response effect of growth factors on DNA synthesis
in normal dermal fibroblasts (a) and of PDGF-BB in chronic
wound, acute wound, and normal dermal fibroblasts (b). Mitogenesis
was determined in growth-arrested cells as BrdU incorporation (see Materials
and Methods). The mitogenic response to the growth factors of the different
fibroblast strains was expressed as fold increase over medium used for the
growth factors alone. Error bars are omitted for reasons of clarity.
with skin fibroblasts, we also included fibroblasts from acute wounds
to control for the influence of wound environment on fibroblasts
(Regan et al, 1991; Germain et al, 1994; Ågren et al, 1996).
Our patients with venous leg ulcers were older than the patients
with acute wounds and the healthy volunteers. Furthermore, the
location of the source of the fibroblasts differed among the three
groups. There appears, however, to be a disagreement on the
influence of donor age and anatomic location on fibroblast functions
(Cristofalo, 1996). In fact some investigators found no effect of
donor age and anatomic location on fibroblast growth (Falanga
et al, 1991; Cristofalo, 1996; Vande Berg et al, 1998). In our study,
the age of the chronic wounds rather than the age of the donor
patients was a more important determinant of cell replication rates,
because the patients with the slowest growing wound fibroblasts
468 ÅGREN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Table III. Chronic wound fibroblasts displayed a decreased
maximal mitogenic response to growth factorsa
Chronic Acute Normal
wounds wounds dermis
Growth factor (n 5 4) (n 5 5) (n 5 5)
Control (no 0 0 0
growth factor)
PDGF-BB 5.9 6 2.4b 15.2 6 7.0 15.0 6 1.6
PDGF-AA 1.5 6 0.6 4.6 6 2.6 6.6 6 1.0
bFGF 2.5 6 0.9 9.3c 8.5 6 0.9
EGF 2.5 6 1.2 8.9c 6.0 6 0.6
TGF-β1 0.8 6 0.8 0.2c 0.6 6 0.2
aExpressed as fold increase over control (no growth factor).
bMean 6 1 SEM.
cOnly one strain from the acute wounds was tested for mitogenic response to
bFGF, EGF, and TGF-β1.
were younger (aged 64 6 8 y, n 5 5) than the patients (74 6 2 y,
n 5 3) with more rapidly growing cells.
The chronic wound fibroblasts showed a generally diminished
mitogenic response to growth factors (Table III). Stanley et al
(1997) reported similar results to ours with bFGF and EGF. The
mitogenic response to PDGF-BB of chronic wound fibroblasts was
also decreased. This may provide one explanation for the poor
response to topical PDGF-BB seen in some cases (Pierce et al, 1994).
The decreased mitogenic effect of PDGF-BB on chronic wound
fibroblasts did not appear to be due to fewer PDGF α-receptors
or β-receptors. Preliminary studies indicated that the levels of EGF
receptors, measured with an ELISA assay (Christensen et al, 1995),
did not differ among the three groups either (E. Nexø, personal
communication, 1996). The decreased mitogenic response to
growth factors may be due to a reduced affinity of the receptors
and/or a defective signal transduction in the chronic wound
fibroblasts.
PDGF receptor levels of the α-subunits and β-subunits were
similar for the dermal and wound fibroblast strains, although there
were slightly more β-receptors than α-receptors on the normal
dermal fibroblasts. This finding is in sharp contrast to that of other
studies where 5–10-fold higher levels of β-receptors on dermal
fibroblasts were found (Ichiki et al, 1995; Petri et al, 1997). These
investigators used western blotting or flow cytometric techniques.
Because our culture medium was optimized by supplementation
with bFGF it is possible that the α-receptor was selectively
upregulated under these culture conditions (Ichiki et al, 1995). On
the other hand, Karlsson and Paulsson (1994) found similar levels
of α-receptors and β-receptors in cultured human skin fibroblasts
using a binding assay with radio-iodinated PDGF-AA and
PDGF-BB.
Decreased growth and mitogenic response to growth factors of
chronic wound fibroblasts, and possibly of other effector cells, such
as keratinocytes and endothelial cells, may be a general intrinsic
abnormality in some chronic wounds. The phenotype of some of
our cultured fibroblasts resembles those of in vitro aged fibroblasts
classified as phase III cells by Hayflick and Moorhead (1961), i.e.,
a reduced or a total loss of ability to pass from the G1 phase into
S phase of the cell cycle. It is interesting to note that patients with
Werner’s syndrome characterized by accelerated aging, commonly
develop non-healing ulcers on the lower leg, although the etiology
appears to be excessive pressure rather than a primary vascular
defect (Hu¨rlimann and Schnyder, 1991). Skin fibroblasts cultured
from these patients grow slowly and the responsiveness to PDGF
and FGF is diminished without a concomitant change in the
number of receptors for respective growth factor (Bauer et al, 1986).
It is unclear what causes the phenotypic changes of fibroblasts
in chronic venous leg ulcers. It has been shown, however, that the
production of free oxygen radicals is elevated in venous disease
(Whiston et al, 1994). Oxidative stress induces irreversible changes,
such as diminished cell growth and growth factor response, and an
altered morphology, in cultured human diploid fibroblasts (Chen
Figure 4. PDGF a-receptor and b-receptor levels in dermal, chronic
wound and acute wound fibroblasts. Fibroblast membrane extracts
(200 µl diluted extract was added to each slot) from normal dermis (top
three horizontal bands in each blot), from chronic wounds (middle three
horizontal bands), and from acute wounds (bottom three horizontal bands)
were filtered through a nitrocellulose membrane, which was probed with
monoclonal antibodies against the PDGF α-receptor (a) and the PDGF β-
receptor (b), respectively. Left three vertical bands in each blot represent a
1:2000 dilution of extract, middle three vertical bands in each blot a 1:1000
dilution, and the right three vertical bands in each blot a 1:500 dilution.
PDGF α-receptor and β-receptor levels were determined by densitometry
of the slot-blots (see Materials and Methods). There was no statistically
significant difference among dermal (n 5 5), chronic wound (n 5 8), and
acute wound (n 5 10) fibroblasts regarding the levels of α-receptors or β-
receptors (α-receptors, p 5 0.683; β-receptors, p 5 0.842) (c). Error
bars: SEM.
and Ames, 1994). Encouraging results with treatment of venous
ulcerations with pentoxifylline and with topical sulfydryl-containing
agents that bind oxygen-derived free radicals have also been
reported (Salim, 1992; Coleridge Smith, 1994). It is also possible
that the fibroblasts have exhausted their proliferative capacity
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because of repetitive replication due to the chronic inflammation
leading to the production of mitogenic cytokines (Vande Berg
et al, 1998).
Although we studied only cell proliferation it is tempting to
speculate that chronic wound fibroblasts suffer from other functional
deficiencies, as loss of cell proliferation is commonly associated
with other cellular changes (Cristofalo, 1996). For example,
fibroblasts from venous leg ulcers appear to make less collagen than
fibroblasts from normal skin, possibly due to a decreased response
to TGF-β1 (Herrick et al, 1996; Hasan et al, 1997).
It should be emphasized that the chronic wounds studied
represent severe cases not responding to conservative treatment,
the only remaining alternative being transplantation with a split
skin graft.
Because our findings are based on in vitro studies there is a
question of phenotype stability of the fibroblasts when taken from
their original environment to culture conditions. Cells, however,
were analyzed at an early passage and in vitro cultured cells generally
reflect the basic processes taking place in vivo, although the dynamics
may differ (Cristofalo, 1996; Vande Berg et al, 1998). Owing to
heterogeneity among fibroblasts in wounds, an error may also have
been introduced by using an explant procedure possibly favoring
the most rapidly growing fibroblasts (Vande Berg et al, 1998). We
could not see a major difference, however, in the replication of
fibroblasts obtained from explants compared with those obtained
after enzymatic digestion of granulation tissue.
We hypothesize that old chronic wounds are populated by
fibroblasts or subpopulation of fibroblasts that are exhausted/
dysfunctional with a limited ability to replicate, and possibly to
produce proper extracellular matrix elements and keratinocyte-
stimulating factors (Werner et al, 1994).
In conclusion, our cellular findings provide one explanation for
the failure of some chronic venous leg ulcers to heal, which opens
up areas of investigation for new treatment strategies.
The excellent technical assistance of Mette Villingshøj is acknowledged. Coloplast
A/S, Denmark funded the study and Sally Dabelsteen was supported by a grant
(2411271 SSVF 12–2298, 9600821).
REFERENCES
Ågren MS, Haisa M, Grotendorst GR: Differential expression of platelet-derived
growth factor receptors in porcine fibroblasts cultured from skin and granulation
tissue. Wound Repair Regeneration 4:288–296, 1996
Bauer EA, Silverman N, Busiek DF, Kronberger A, Deuel TF: Diminished response
of Werner’s syndrome fibroblasts to growth factors PDGF and FGF. Science
234:1240–1243, 1986
Bouissou H, Pieraggi M, Julian M, Uhart D, Kokolo J: Fibroblasts in dermal tissue
repair. Electron microscopic and immunohistochemical study. Int J Dermatol
27:564–570, 1988
Bruce SA, Deamond SF: Longitudinal study of in vivo wound repair and in vitro
cellular senescence of dermal fibroblasts. Exp Gerontol 26:17–27, 1991
Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A: Circulating fibrocytes define
a new leukocyte subpopulation that mediates tissue repair. Mol Med 1:71–
81, 1994
Chen Q, Ames BN: Senescence-like growth arrest induced by hydrogen peroxide
in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 91:4130–
4134, 1994
Christensen ME, Engbæk F, Therkildsen MH, Bretlau P, Nexø E: A sensitive
enzyme-linked immunosorbent assay used for quantitation of epidermal growth
factor receptor protein in head and neck carcinomas: evaluation, interpretations
and limitations. Br J Cancer 72:1487–1493, 1995
Coleridge Smith PD: Venous ulcer. Br J Surg 81:1404–1405, 1994
Cristofalo VJ: Ten years later: what have we learned about human aging from studies
of cell cultures? Gerontologist 36:737–741, 1996
Falanga V, Katz MH, Goodless DR: Proliferation and collagen synthesis by human
dermal fibroblasts cultured from different body sites. J Dermatol Sci 2:166–
170, 1991
Falanga V, Grinell F, Gilchrest B, Maddox YT, Moshell A: Workshop on the
pathogenesis of chronic wounds. J Invest Dermatol 102:125–127, 1994
Freshney RI: Culture of animal cells. A Manual of Basic Technique, 2nd edn. New
York: Wiley-Liss., 1991
Germain L, Jean A, Auger FA, Garrel DR: Human wound healing fibroblasts have
greater contractile properties than dermal fibroblasts. J Surg Res 57:268–
273, 1994
Grotendorst GR, Martin GR, Pencev D, Sodek J, Harvey AK: Stimulation of
granulation tissue formation by platelet-derived growth factor in normal and
diabetic rats. J Clin Invest 76:2323–2329, 1985
Hart CE, Seifert RA, Ross R, Bowen-Pope DF: Synthesis, phosphorylation, and
degradation of multiple forms of the platelet-derived growth factor receptor
studied using a monoclonal antibody. J Biol Chem 262:10780–10785, 1987
Hasan A, Murata H, Falabella A, Ochoa S, Zhou L, Badiavas E, Falanga V: Dermal
fibroblasts from venous ulcers are unresponsive to the action of transforming
growth factor-β1. J Dermatol Sci 16:59–66, 1997
Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp
Cell Res 25:585–621, 1961
Herrick SE, Ireland GW, Simon D, McCollum CN, Ferguson MWJ: Venous ulcer
fibroblasts compared with normal fibroblasts show differences in collagen but
not fibronectin production under both normal and hypoxic conditions. J Invest
Dermatol 106:187–193, 1996
Hu¨rlimann AF, Schnyder UW: Werner-Syndrom mit torpiden trophischen ulcera
cruris. Hautarzt 42:721–725, 1991
Ichiki Y, Smith E, LeRoy EC, Trojanowska M: Different effects of basic fibroblast
growth factor and transforming growth factor-β on the two platelet-derived
growth factor receptors’ expression in scleroderma and healthy human dermal
fibroblasts. J Invest Dermatol 104:124–127, 1995
Jorgensen LN, Kallehave F, Karlsmark T, Gottrup F: Reduced collagen accumulation
after major surgery. Br J Surg 83:1591–1594, 1996
Karlsson C, Paulsson Y: Age related induction of platelet-derived growth factor A-
chain mRNA in normal human fibroblasts. J Cell Physiol 158:256–262, 1994
Petri JB, Ko¨nig S, Haupt B, Haustein UF, Herrmann K: Molecular analysis of
different phases in human wound healing. Exp Dermatol 6:133–139, 1997
Peus D, Jungta¨ubl H, Knaub S, et al: Localization of platelet-derived growth factor
receptor subunit expression in chronic venous leg ulcers. Wound Repair
Regeneration 3:265–272, 1995
Pierce GF, Tarpley JE, Allman RA, et al: Tissue repair processes in healing chronic
pressure ulcers treated with recombinant platelet-derived growth factor BB.
Am J Pathol 145:1399–1410, 1994
Regan MC, Kirk SJ, Wasserkrug HL, Barbul A: The wound environment as a
regulator of fibroblast phenotype. J Surg Res 50:442–448, 1991
Reuterdahl C, Sundberg C, Rubin K, Funa K, Gerdin B: Tissue localization of
β receptors for platelet-derived growth factor and platelet-derived growth
factor B chain during wound repair in humans. J Clin Invest 91:2065–2075, 1993
Roberts GP, Harding KG: Stimulation of glycosaminoglycan synthesis in cultured
fibroblasts by hyperbaric oxygen. Br J Dermatol 131:630–633, 1994
Robson MC: The role of growth factors in the healing of chronic wounds. Wound
Repair Regeneration 5:12–17, 1997
Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF: Platelet-derived
growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23–
25, 1992
Salim AS: Role of sulphydryl-containing agents in the management of venous
(varicose) ulceration. A new approach. Clin Exp Dermatol 17:427–432, 1992
Stanley AC, Park H-Y, Phillips TJ, Russakovsky V, Menzoian JO: Reduced growth
of dermal fibroblasts from chronic venous ulcers can be stimulated with growth
factors. J Vasc Surg 26:994–1001, 1997
Steenfos HH: Growth factors and wound healing. Scand J Plast Reconstr Surg Hand
Surg 28:95–105, 1994
Towbin H, Gordon J: Immunoblotting and dot immunobinding—current status and
outlook. J Immunol Methods 72:313–340, 1984
Vande Berg JS, Rudolph R, Hollan C, Haywood-Reid PL: Fibroblast senescence
in pressure ulcers. Wound Repair and Regeneration 6:38–49, 1998
Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH, Williams
LT: The function of KGF in morphogenesis of epithelium and reepithelialization
of wounds. Science 266:819–822, 1994
Whiston RJ, Hallett MB, Davies EV, Harding KG, Lane IF: Inappropriate neutrophil
activation in venous disease. Br J Surg 81:695–698, 1994
